HC Wainwright Issues Positive Forecast for Halozyme Therapeutics (NASDAQ:HALO) Stock Price

Halozyme Therapeutics (NASDAQ:HALO) had its price target boosted by HC Wainwright from $68.00 to $70.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on the company. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Finally, JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $61.44.

Halozyme Therapeutics Stock Down 1.8 %

HALO stock opened at $52.80 on Friday. The firm has a market cap of $6.72 billion, a PE ratio of 17.48, a PEG ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 1 year low of $33.15 and a 1 year high of $65.53. The company has a fifty day simple moving average of $50.23 and a 200 day simple moving average of $54.00. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $49,000. GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 350 shares in the last quarter. Toth Financial Advisory Corp bought a new stake in Halozyme Therapeutics in the third quarter valued at $57,000. FSC Wealth Advisors LLC acquired a new position in Halozyme Therapeutics during the third quarter worth $65,000. Finally, Park Place Capital Corp lifted its holdings in shares of Halozyme Therapeutics by 828.1% during the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 1,209 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.